Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges.

Alhallak, Kinan; Sun, Jennifer; Jeske, Amanda; Park, Chaelee; Yavner, Jessica; Bash, Hannah; Lubben, Berit; Adebayo, Ola; Khaskiah, Ayah; Azab, Abdel Kareem

Alhallak, Kinan; Sun, Jennifer; Jeske, Amanda; Park, Chaelee; Yavner, Jessica; Bash, Hannah; Lubben, Berit; Adebayo, Ola; Khaskiah, Ayah; Azab, Abdel Kareem.

Afiliação

Alhallak K; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Sun J; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
Jeske A; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Park C; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
Yavner J; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Bash H; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
Lubben B; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Adebayo O; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Khaskiah A; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Azab AK; Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.

Cancers (Basel) ; 13(12)2021 Jun 08.

Article em En | MEDLINE | ID: mdl-34201007

ABSTRACT

ABSTRACT

MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.

Palavras-chave

bispecific T cell engagers; chimeric antigen receptor-T cells; multiple myeloma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links